Skip to main content
SpringerLink
Log in

Novel Approaches for HDL-Directed Therapies

  • Nonstatin Drugs (E. deGoma, Section Editor)
  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

High-density lipoproteins (HDL) are thought to exert a protective role against atherosclerosis. The measurement of the cholesterol mass within HDL (HDL-C) represents a good biomarker of cardiovascular health, but HDL-C appears to be a poor therapeutic target. Here, we discuss new targets for the development of HDL-directed therapies.

Recent Findings

Among cardio-protective functions of HDL particles, the ability of HDL to remove cholesterol from cells involved in the early stages of atherosclerosis is considered one of the most important functions. This process, termed “HDL biogenesis,” is initiated by the formation of highly specialized plasma membrane micro-domains by the ATP-binding cassette transporter A1 (ABCA1) and the binding of apolipoproteins (apo) such as apoA-I, the major protein moiety of HDL, to the micro-domains. Although early strategies aimed at increasing HDL biogenesis by upregulating ABCA1 or apoA-I gene expression have not met with clinical success, recent advances in understanding transcriptional, post-transcriptional, and post-translational regulatory pathways propose new targets for the promotion of HDL biogenesis. We have recently reported that a novel apoA-I-binding protein desmocollin 1 (DSC1) prevents HDL biogenesis and that inhibition of apoA-I-DSC1 interactions promotes HDL biogenesis by stabilizing ABCA1. This new HDL regulation pathway nominates DSC1 as an attractive pharmacological target.

Summary

In the absence of clinically useful therapy to increase HDL biogenesis, finding novel targets to unlock the therapeutic potential of HDL is highly desired. Modulation of apoA-I-DSC1 interactions may be a viable strategy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380(9841):572–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Ko DT, Alter DA, Guo H, Koh M, Lau G, Austin PC, et al. High-density lipoprotein cholesterol and cause-specific mortality in individuals without previous cardiovascular conditions: the CANHEART study. J Am Coll Cardiol. 2016;68(19):2073–83.

    Article  CAS  PubMed  Google Scholar 

  3. • Madsen CM, Varbo A, Nordestgaard BG. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. Eur Heart J. 2017;38:2478–86. Demonstrate complex associations between HDL cholesterol levels and cardiovascular disease and mortality.

    Article  PubMed  Google Scholar 

  4. Boekholdt SM, Arsenault BJ, Hovingh GK, Mora S, Pedersen TR, Larosa JC, et al. Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis. Circulation. 2013;128(14):1504–12.

    Article  CAS  PubMed  Google Scholar 

  5. Kingwell BA, Chapman MJ, Kontush A, Miller NE. HDL-targeted therapies: progress, failures and future. Nat Rev Drug Discov. 2014;13(6):445–64.

    Article  CAS  PubMed  Google Scholar 

  6. Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med. 2017;376(20):1933–42.

    Article  PubMed  Google Scholar 

  7. Luscher TF, Landmesser U, von Eckardstein A, Fogelman AM. High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target. Circ Res. 2014;114(1):171–82.

    Article  PubMed  Google Scholar 

  8. • Choi HY, Hafiane A, Schwertani A, Genest J. High-density lipoproteins: biology, epidemiology, and clinical management. Can J Cardiol. 2017;33(3):325–33. Athero-protective HDL functionality and therapeutic potential of HDL are reviewed.

    Article  PubMed  Google Scholar 

  9. Marz W, Kleber ME, Scharnagl H, Speer T, Zewinger S, Ritsch A, et al. HDL cholesterol: reappraisal of its clinical relevance. Clin Res Cardiol. 2017; https://doi.org/10.1007/s00392-017-1106-1.

  10. Hafiane A, Genest J. HDL, atherosclerosis, and emerging therapies. Cholesterol. 2013;2013:891403.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Vaisar T, Tang C, Babenko I, Hutchins P, Wimberger J, Suffredini AF, et al. Inflammatory remodeling of the HDL proteome impairs cholesterol efflux capacity. J Lipid Res. 2015;56(8):1519–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Kontush A, Lhomme M, Chapman MJ. Unraveling the complexities of the HDL lipidome. J Lipid Res. 2013;54(11):2950–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364(2):127–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014;371(25):2383–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Khera AV, Demler OV, Adelman SJ, Collins HL, Glynn RJ, Ridker PM, et al. Cholesterol efflux capacity, high-density lipoprotein particle number, and incident cardiovascular events: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). Circulation. 2017;135(25):2494–504.

    Article  CAS  PubMed  Google Scholar 

  16. •• Qian H, Zhao X, Cao P, Lei J, Yan N, Gong X. Structure of the human lipid exporter ABCA1. Cell. 2017;169(7):1228–39 e10. Cryo-electron microscopy structure of the human ABCA1 provides insight into the action mechanism of ABCA1.

    Article  CAS  PubMed  Google Scholar 

  17. Iatan I, Bailey D, Ruel I, Hafiane A, Campbell S, Krimbou L, et al. Membrane microdomains modulate oligomeric ABCA1 function: impact on apoAI-mediated lipid removal and phosphatidylcholine biosynthesis. J Lipid Res. 2011;52(11):2043–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Phillips MC. Molecular mechanisms of cellular cholesterol efflux. J Biol Chem. 2014;289(35):24020–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. • Segrest JP, Jones MK, Catte A, Manchekar M, Datta G, Zhang L, et al. Surface density-induced pleating of a lipid monolayer drives nascent high-density lipoprotein assembly. Structure. 2015;23(7):1214–26. Propose a mechanism for the creation of specialized plasma membrane micro-domains required for the assembly of HDL.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Rosenson RS, Brewer HB Jr, Davidson WS, Fayad ZA, Fuster V, Goldstein J, et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation. 2012;125(15):1905–19.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 1991;353(6341):265–7.

    Article  CAS  PubMed  Google Scholar 

  22. Paszty C, Maeda N, Verstuyft J, Rubin EM. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest. 1994;94(2):899–903.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Zannis VI, Duka A, Drosatos K, Sanoudou D, Koukos G, Zanni E, et al. Regulation of apoA-I gene expression and prospects to increase plasma apoA-I and HDL levels. In: Schaefer EJ, editor. High density lipoproteins, dyslipidemia, and coronary heart disease. New York: Springer; 2010. p. 15–24.

    Chapter  Google Scholar 

  24. Staels B, Auwerx J. Role of PPAR in the pharmacological regulation of lipoprotein metabolism by fibrates and thiazolidinediones. Curr Pharm Des. 1997;3:1–14.

    CAS  Google Scholar 

  25. Khera AV, Millar JS, Ruotolo G, Wang MD, Rader DJ. Potent peroxisome proliferator-activated receptor-alpha agonist treatment increases cholesterol efflux capacity in humans with the metabolic syndrome. Eur Heart J. 2015;36(43):3020–2.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Guo Y, Fan Y, Zhang J, Lomberk GA, Zhou Z, Sun L, et al. Perhexiline activates KLF14 and reduces atherosclerosis by modulating apoA-I production. J Clin Invest. 2015;125(10):3819–30.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Picaud S, Wells C, Felletar I, Brotherton D, Martin S, Savitsky P, et al. RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. Proc Natl Acad Sci U S A. 2013;110(49):19754–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. McLure KG, Gesner EM, Tsujikawa L, Kharenko OA, Attwell S, Campeau E, et al. RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist. PLoS One. 2013;8(12):e83190.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Shao B, Tang C, Sinha A, Mayer PS, Davenport GD, Brot N, et al. Humans with atherosclerosis have impaired ABCA1 cholesterol efflux and enhanced high-density lipoprotein oxidation by myeloperoxidase. Circ Res. 2014;114(11):1733–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Huang Y, DiDonato JA, Levison BS, Schmitt D, Li L, Wu Y, et al. An abundant dysfunctional apolipoprotein A1 in human atheroma. Nat Med. 2014;20(2):193–203.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. DiDonato JA, Huang Y, Aulak KS, Even-Or O, Gerstenecker G, Gogonea V, et al. Function and distribution of apolipoprotein A1 in the artery wall are markedly distinct from those in plasma. Circulation. 2013;128(15):1644–55.

    Article  CAS  PubMed  Google Scholar 

  32. Remaley AT, Stonik JA, Demosky SJ, Neufeld EB, Bocharov AV, Vishnyakova TG, et al. Apolipoprotein specificity for lipid efflux by the human ABCAI transporter. Biochem Biophys Res Commun. 2001;280(3):818–23.

    Article  CAS  PubMed  Google Scholar 

  33. Hara H, Hara H, Komaba A, Yokoyama S. Alpha-helical requirements for free apolipoproteins to generate HDL and to induce cellular lipid efflux. Lipids. 1992;27(4):302–4.

    Article  CAS  PubMed  Google Scholar 

  34. Hafiane A, Genest J. ATP binding cassette A1 (ABCA1) mediates microparticle formation during high-density lipoprotein (HDL) biogenesis. Atherosclerosis. 2017;257:90–9.

    Article  CAS  PubMed  Google Scholar 

  35. Nandi S, Ma L, Denis M, Karwatsky J, Li Z, Jiang XC, et al. ABCA1-mediated cholesterol efflux generates microparticles in addition to HDL through processes governed by membrane rigidity. J Lipid Res. 2009;50(3):456–66.

    Article  CAS  PubMed  Google Scholar 

  36. Costet P, Luo Y, Wang N, Tall AR. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J Biol Chem. 2000;275(36):28240–5.

    CAS  PubMed  Google Scholar 

  37. Venkateswaran A, Laffitte BA, Joseph SB, Mak PA, Wilpitz DC, Edwards PA, et al. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc Natl Acad Sci U S A. 2000;97(22):12097–102.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Hong C, Tontonoz P. Liver X receptors in lipid metabolism: opportunities for drug discovery. Nat Rev Drug Discov. 2014;13(6):433–44.

    Article  CAS  PubMed  Google Scholar 

  39. Chu K, Miyazaki M, Man WC, Ntambi JM. Stearoyl-coenzyme a desaturase 1 deficiency protects against hypertriglyceridemia and increases plasma high-density lipoprotein cholesterol induced by liver X receptor activation. Mol Cell Biol. 2006;26(18):6786–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Joseph SB, Laffitte BA, Patel PH, Watson MA, Matsukuma KE, Walczak R, et al. Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J Biol Chem. 2002;277(13):11019–25.

    Article  CAS  PubMed  Google Scholar 

  41. Talukdar S, Hillgartner FB. The mechanism mediating the activation of acetyl-coenzyme A carboxylase-alpha gene transcription by the liver X receptor agonist T0-901317. J Lipid Res. 2006;47(11):2451–61.

    Article  CAS  PubMed  Google Scholar 

  42. Liang G, Yang J, Horton JD, Hammer RE, Goldstein JL, Brown MS. Diminished hepatic response to fasting/refeeding and liver X receptor agonists in mice with selective deficiency of sterol regulatory element-binding protein-1c. J Biol Chem. 2002;277(11):9520–8.

    Article  CAS  PubMed  Google Scholar 

  43. Repa JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro JM, Shimomura I, et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev. 2000;14(22):2819–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Hien HTM, Ha NC, Thom LT, Hong DD. Squalene promotes cholesterol homeostasis in macrophage and hepatocyte cells via activation of liver X receptor (LXR) alpha and beta. Biotechnol Lett. 2017;39:1101–7.

    Article  CAS  PubMed  Google Scholar 

  45. Canfran-Duque A, Lin CS, Goedeke L, Suarez Y, Fernandez-Hernando C. Micro-RNAs and high-density lipoprotein metabolism. Arterioscler Thromb Vasc Biol. 2016;36(6):1076–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Li Z, Rana TM. Therapeutic targeting of microRNAs: current status and future challenges. Nat Rev Drug Discov. 2014;13(8):622–38.

    Article  CAS  PubMed  Google Scholar 

  47. Najafi-Shoushtari SH, Kristo F, Li Y, Shioda T, Cohen DE, Gerszten RE, et al. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science. 2010;328(5985):1566–9.

    Article  CAS  PubMed  Google Scholar 

  48. Rayner KJ, Suarez Y, Davalos A, Parathath S, Fitzgerald ML, Tamehiro N, et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science. 2010;328(5985):1570–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. • Goldstein JL, Brown MS. A century of cholesterol and coronaries: from plaques to genes to statins. Cell. 2015;161(1):161–72. Outstanding review on past, present, and future studies of cholesterol.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Ono K. Functions of microRNA-33a/b and microRNA therapeutics. J Cardiol. 2016;67(1):28–33.

    Article  PubMed  Google Scholar 

  51. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell. 1997;89(3):331–40.

    Article  CAS  PubMed  Google Scholar 

  52. Chen G, Liang G, Ou J, Goldstein JL, Brown MS. Central role for liver X receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver. Proc Natl Acad Sci U S A. 2004;101(31):11245–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Kimura Y, Tamasawa N, Matsumura K, Murakami H, Yamashita M, Matsuki K, et al. Clinical significance of determining plasma MicroRNA33b in type 2 diabetic patients with dyslipidemia. J Atheroscler Thromb. 2016;23(11):1276–85.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Munehira Y, Ohnishi T, Kawamoto S, Furuya A, Shitara K, Imamura M, et al. Alpha1-syntrophin modulates turnover of ABCA1. J Biol Chem. 2004;279(15):15091–5.

    Article  CAS  PubMed  Google Scholar 

  55. Arakawa R, Yokoyama S. Helical apolipoproteins stabilize ATP-binding cassette transporter A1 by protecting it from thiol protease-mediated degradation. J Biol Chem. 2002;277(25):22426–9.

    Article  CAS  PubMed  Google Scholar 

  56. Lv YC, Yin K, Fu YC, Zhang DW, Chen WJ, Tang CK. Posttranscriptional regulation of ATP-binding cassette transporter A1 in lipid metabolism. DNA Cell Biol. 2013;32(7):348–58.

    Article  CAS  PubMed  Google Scholar 

  57. Wang L, Palme V, Rotter S, Schilcher N, Cukaj M, Wang D, et al. Piperine inhibits ABCA1 degradation and promotes cholesterol efflux from THP-1-derived macrophages. Mol Nutr Food Res. 2017;61(4).

  58. Huang L, Fan B, Ma A, Shaul PW, Zhu H. Inhibition of ABCA1 protein degradation promotes HDL cholesterol efflux capacity and RCT and reduces atherosclerosis in mice. J Lipid Res. 2015;56(5):986–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Huang X, Dixit VM. Drugging the undruggables: exploring the ubiquitin system for drug development. Cell Res. 2016;26(4):484–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Ogura M, Ayaori M, Terao Y, Hisada T, Iizuka M, Takiguchi S, et al. Proteasomal inhibition promotes ATP-binding cassette transporter A1 (ABCA1) and ABCG1 expression and cholesterol efflux from macrophages in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2011;31(9):1980–7.

    Article  CAS  PubMed  Google Scholar 

  61. Mizuno T, Hayashi H, Naoi S, Sugiyama Y. Ubiquitination is associated with lysosomal degradation of cell surface-resident ATP-binding cassette transporter A1 (ABCA1) through the endosomal sorting complex required for transport (ESCRT) pathway. Hepatology. 2011;54(2):631–43.

    Article  CAS  PubMed  Google Scholar 

  62. Hsieh V, Kim MJ, Gelissen IC, Brown AJ, Sandoval C, Hallab JC, et al. Cellular cholesterol regulates ubiquitination and degradation of the cholesterol export proteins ABCA1 and ABCG1. J Biol Chem. 2014;289(11):7524–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. •• Choi HY, Ruel I, Malina A, Garrod DR, Oda MN, Pelletier J, et al. Desmocollin 1 is abundantly expressed in atherosclerosis and impairs high-density lipoprotein biogenesis. Eur Heart J. 2017; https://doi.org/10.1093/eurheartj/ehx340. Desmocollin 1 is identified as a novel apoA-I-binding protein involved in the formation of HDL.

  64. Rajapaksha M, Kaur J, Bose M, Whittal RM, Bose HS. Cholesterol-mediated conformational changes in the steroidogenic acute regulatory protein are essential for steroidogenesis. Biochemistry. 2013;52(41):7242–53.

    Article  CAS  PubMed  Google Scholar 

  65. Grouleff J, Irudayam SJ, Skeby KK, Schiott B. The influence of cholesterol on membrane protein structure, function, and dynamics studied by molecular dynamics simulations. Biochim Biophys Acta. 2015;1848(9):1783–95.

    Article  CAS  PubMed  Google Scholar 

  66. Gao Y, Zhou Y, Goldstein JL, Brown MS, Radhakrishnan A. Cholesterol-induced conformation changes in the sterol-sensing domain of the scap protein suggest feedback mechanism to control cholesterol synthesis. J Biol Chem. 2017;292:8729–37.

    Article  CAS  PubMed  Google Scholar 

  67. Hafiane A, Genest J. High density lipoproteins: measurement techniques and potential biomarkers of cardiovascular risk. BBA Clin. 2015;3:175–88.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This work was supported by a grant from the Canadian institutes of Health Research (CIHR MOP 15042 JG).

Author information

Authors and Affiliations

  1. The Research Institute of the McGill University Health Center, 1001 boul. Decarie Bloc E, Office EM12212, Montreal, Québec, H4A 3J1, Canada

    Jacques Genest & Hong Y. Choi

Authors
  1. Jacques Genest
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hong Y. Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hong Y. Choi.

Ethics declarations

Conflict of Interest

Jacques Genest and Hong Y. Choi declare no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Nonstatin Drugs

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Genest, J., Choi, H.Y. Novel Approaches for HDL-Directed Therapies. Curr Atheroscler Rep 19, 55 (2017). https://doi.org/10.1007/s11883-017-0699-1

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11883-017-0699-1

Keywords

Search

Navigation